Overview

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety of sorafenib and vorinostat when given together to see what effects (good and bad) it has on the patient and their acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). This study is also being done to find the highest dose of sorafenib and vorinostat that can be given together without causing severe side effects.

Phase:

Phase 1

Details

Lead Sponsor:

Indiana University School of Medicine

Collaborator:

Bayer

Treatments:

Niacinamide
Sorafenib
Vorinostat